v3.25.1
Condensed Consolidated Statements of Operations and Comprehensive Loss (unaudited) - USD ($)
3 Months Ended
Mar. 31, 2025
Mar. 31, 2024
Revenue    
Product revenue $ 1,101,605 $ 840,354
Cost of goods sold 774,765 561,484
Gross profit 326,840 278,870
Operating expenses:    
Research and development 1,529,795 215,134
Selling, general and administrative 6,749,381 5,878,546
Total operating expenses 8,279,176 6,093,680
Loss from operations (7,952,336) (5,814,810)
Other (expense) income:    
Foreign exchange transaction loss (61,470) (24,343)
Change in fair value of share liability 12,500 (218,000)
Change in fair value of convertible notes payable (957,408) (953,710)
Interest income 513,713 12,188
Interest expense (87,151) (13,788)
Total other expense (579,816) (1,197,653)
Loss before income tax expense (8,532,152) (7,012,463)
Income tax benefit 70,720 47,619
Net loss before allocation to noncontrolling interests (8,461,432) (6,964,844)
Less: Net loss attributable to noncontrolling interests (15,235) (16,759)
Net loss attributable to ASP Isotopes Inc. shareholders $ (8,446,197) $ (6,948,085)
Net loss per share, attributable to ASP Isotopes Inc. shareholders, basic $ (0.12) $ (0.16)
Net loss per share, attributable to ASP Isotopes Inc. shareholders, diluted $ (0.12) $ (0.16)
Weighted average shares of common stock outstanding, basic 69,484,200 44,561,844
Weighted average shares of common stock outstanding, diluted 69,484,200 44,561,844
Comprehensive loss:    
Net loss before allocation to noncontrolling interests $ (8,461,432) $ (6,964,844)
Foreign currency translation 1,170,701 (543,729)
Total comprehensive loss before allocation to noncontrolling interests (7,290,731) (7,508,573)
Less: Comprehensive loss attributable to noncontrolling interests (1,466) (7,530)
Total comprehensive loss $ (7,289,265) $ (7,501,043)

Source